Extended-release niacin raises adiponectin and leptin

Westphal, Sabine; Borucki, Katrin; Taneva, Elina; Makarova, Ruma; Luley, Claus

doi:10.1016/j.atherosclerosis.2006.06.028

Cited by 72 publications

(63 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, when niacin (200 mg/kg per day for 6 wk) was administered to hypercholesterolemic rabbits, serum leptin concentrations decreased by 22% [41] . Yet, data collected from two separate human studies support the notion that niacin actually increases circulating leptin concentrations [42,43] . These studies were conducted in humans with either metabolic syndrome or T2DM.…”

Section: Leptinmentioning

confidence: 86%

“…These studies were conducted in humans with either metabolic syndrome or T2DM. Westphal et al [44] found that six weeks of extended-release niacin (1500 mg/d) resulted in a 27% increase in serum leptin concentrations in men with the metabolic syndrome. In addition, a small study examined the effects of acipimox, a nicotinic acid analogue, in humans with T2DM.…”

Section: Leptinmentioning

confidence: 99%

“…Each study that has examined the response of adiponectin to niacin administration has found that adiponectin increases as a result of niacin treatment (Table 3) [39,40,44,103,104] . Westphal and colleagues reported that serum total adiponectin concentrations increased by 54% in humans after four weeks of extended-release niacin (1000 mg/d) and by 94% after 6 wk (1500 mg/d) in patients with cardiovascular disease [40] .…”

Section: Adiponectinmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacological effects of lipid-lowering drugs on circulating adipokines

Wanders

Plaisance²,

Judd³

2010

WJD

View full text Add to dashboard Cite

The cardioprotective effects of lipid-lowering drugs have been primarily attributed to their effects on blood lipid metabolism. However, emerging evidence indicates that lipid-lowering drugs also modulate the synthesis and secretion of adipose tissue-secreted proteins referred to as adipokines. Adipokines influence energy homeostasis and metabolism and have also been shown to modulate the vascular inflammatory cascade. The purpose of this review will be to examine the reported effects of commonly used lipid-lowering drugs (statins, fibrates, niacin and omega-3-fatty acids) on the circulating concentrations of leptin, adiponectin, tumor necrosisfactor-α (TNF-α), Retinol binding protein 4 (RBP4) and resistin. Overall, the lipid-lowering drugs reviewed have minimal effects on leptin and resistin concentrations. Conversely, circulating adiponectin concentrations are consistently increased by each lipid-lowering drug reviewed with the greatest effects produced by niacin. Studies that have examined the effects of statins, niacin and omega-3-fatty acids on TNF-α demonstrate that these agents have little effect on circulating TNF-α concentrations. Niacin and fibrates appear to lower RBP4 but not resistin concentrations. The results of the available studies suggest that a strong relationship exists between pharmacological reductions in blood lipids and adiponectin that is not obvious for other adipokines reviewed.

show abstract

Section: Leptinmentioning

confidence: 86%

Section: Leptinmentioning

confidence: 99%

Section: Adiponectinmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacological effects of lipid-lowering drugs on circulating adipokines

Wanders

Plaisance²,

Judd³

2010

WJD

View full text Add to dashboard Cite

show abstract

“…After careful assessment of full-texts, seven articles were found to fulfill the inclusion criteria and were selected for meta-analysis. [15][16][17][18][19][20][21] Reasons for rejecting the other 12 articles were: not measuring FMD, [29][30][31][32][33][34] not having a randomized design, 35 not including an appropriate control group, 36 FMD not being measured in the brachial artery, 37 insufficient data on baseline and/or endpoint FMD values, 22,38 and not being in the English language. 39 A summary of the study selection process is illustrated in Figure 1.…”

Section: Flow Of Included Studiesmentioning

confidence: 99%

“…However, randomized controlled trials investigating the effects of niacin therapy on the brachial artery FMD have yielded inconsistent results. [15][16][17][18][19][20][21][22] The present study aimed to systematically review the literature and perform a meta-analysis of individual findings on the impact of niacin on FMD.…”

Section: Introductionmentioning

confidence: 99%

Effect of niacin on endothelial function: A systematic review and meta-analysis of randomized controlled trials

Sahebkar

2014

Vasc Med

View full text Add to dashboard Cite

Endothelial dysfunction is an independent predictor of incident atherosclerotic cardiovascular disease (ACVD). Niacin possesses high-density lipoprotein (HDL)-elevating, antioxidant and anti-inflammatory properties, all potentially contributing to the amelioration of endothelial function. However, controversies exist among trials reporting the effects of niacin on endothelium-dependent flow-mediated dilation (FMD) as a reliable surrogate of endothelial function. The objective of this study was to assess the effect of niacin on brachial artery FMD using a meta-analysis of available evidence. MEDLINE and Scopus databases were searched for randomized controlled trials investigating the impact of niacin therapy on brachial artery FMD. Meta-analysis of eligible studies was conducted using a random-effects model. Pooled effects were measured by weighted mean difference (WMD) and 95% confidence intervals (CIs). Quality assessment, and subgroup, meta-regression and sensitivity analyses were conducted using standard methods. Among 596 citations, 19 full-text articles were read and seven were found to be eligible for inclusion. Eligible studies involved 441 subjects comprising 228 in the niacin and 213 in the control groups. Niacin therapy significantly improved FMD (WMD: 1.98%; 95% CI: 0.91-3.05%; p = 0.0003) and this effect was robust in the sensitivity analysis. The effect size was greater in the subgroup of studies administering higher doses of niacin (≥ 2000 mg/day) as well as those studies administering niacin for primary prevention of ACVD. Metaregression indicated no association between niacin-induced changes in FMD and changes in plasma HDL-cholesterol, lowdensity lipoprotein-cholesterol or triglycerides. None of the included studies could find any significant effect of niacin on nitroglycerin-mediated dilation. In conclusion, treatment with niacin improves endothelial function.

show abstract

Extended‐release niacin decreases serum fetuin‐A concentrations in individuals with metabolic syndrome

Kaushik

Plaisance

Kim

et al. 2009

Diabetes Metabolism Res

View full text Add to dashboard Cite

Niacin treatment lowers serum total- and phosphofetuin-A concentrations in individuals with MetS, and these changes correlate with the beneficial changes in serum lipids. Because niacin is known to induce insulin resistance, these findings suggest that fetuin-A may not be a mediator of niacin-induced insulin resistance but it may blunt the insulin resistance induced by niacin by decreasing its circulating concentrations.

show abstract

Extended-release niacin raises adiponectin and leptin

Cited by 72 publications

References 25 publications

Pharmacological effects of lipid-lowering drugs on circulating adipokines

Pharmacological effects of lipid-lowering drugs on circulating adipokines

Effect of niacin on endothelial function: A systematic review and meta-analysis of randomized controlled trials

Extended‐release niacin decreases serum fetuin‐A concentrations in individuals with metabolic syndrome

Contact Info

Product

Resources

About